advertisement
11.4 Prostaglandins (28)
Showing records 1 to 25
Display all abstracts in classification 11.4 Prostaglandins
Search within classification 11.4 Prostaglandins48720 Topical application of 0.005% latanoprost increases episcleral venous pressure in normal dogs
Tsai S; Miller PE; Struble C; Howard S; Almazan A; Burke JA; Hughes PM; Li H; Conforti P; Lee SS; Robinson MR
Veterinary Ophthalmology 2012; 15: 71-78
49017 Meta-analysis of α2-adrenergic agonists versus carbonic anhydrase inhibitors as adjunctive therapy
Cheng JW; Cheng SW; Yu DY; Wei RL; Lu GC
Current Medical Research and Opinion 2012; 28: 543-550
48973 Efficacy of Single Glaucoma Drug in Combined Timolol XE, Latanoprost and Brinzolamide Therapy: A Discontinuation Study
Kobayashi H
Journal of Ocular Pharmacology and Therapeutics 2012; 28: 245-250
48943 Impact of ocular hypotensive lipids on clinically significant diabetic macular edema
Patel AS; Patel CC; Goyal A; Anchala A; Adrean S; Hughes B; Mahmoud TH
European Journal of Ophthalmology 2012; 0: 0
48476 Impact of eyelid closure on the intraocular pressure lowering effect of prostaglandins: a randomised controlled trial
Maul EA; Friedman DS; Quigley HA; Jampel HD
British Journal of Ophthalmology 2012; 96: 250-253
48452 Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost
Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K
Journal of Glaucoma 2012; 21: 60-64
48683 The influence of topical prostaglandin analogues in inflammation after selective laser trabeculoplasty treatment
Ayala M; Chen E
Journal of Ocular Pharmacology and Therapeutics 2012; 28: 118-122
49272 Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study
Katz LJ; Rauchman SH; Cottingham AJ; Simmons ST; Williams JM; Schiffman RM; Hollander DA
Current Medical Research and Opinion 2012; 28: 781-788
48971 Massive choroidal detachment secondary to topical use of bimatoprost: Report of two cases
Cheggour M; Gambrelle J
Journal Français d'Ophtalmologie 2012; 35: 176-180
49040 The influence of central corneal thickness on response to topical prostaglandin analogue therapy
Birt CM; Buys YM; Kiss A; Trope GE;
Canadian Journal of Ophthalmology 2012; 47: 51-54
49003 Randomized Clinical Trial of the Efficacy and Safety of Preservative-free Tafluprost and Timolol in Patients With Open-Angle Glaucoma or Ocular Hypertension
Chabi A; Varma R; Tsai JC; Lupinacci R; Pigeon J; Baranak C; Noble L; Lines C; Ho TW
American Journal of Ophthalmology 2012; 153: 1187-1196
49079 A review of the use of latanoprost for glaucoma since its launch
Digiuni M; Fogagnolo P; Rossetti L
Expert Opinion in Pharmacotherapy 2012; 13: 723-745
48790 Latanoprost 0.005% test formulation is as effective as Xalatan® in patients with ocular hypertension and primary open-angle glaucoma
Allaire C; Dietrich A; Allmeier H; Grundmane I; Mazur-Piotrowska G; Neshev P; Kahle G
European Journal of Ophthalmology 0; 22: 19-27
48964 Iris and periocular adverse reactions to bimatoprost in Japanese patients with glaucoma or ocular hypertension
Inoue K; Shiokawa M; Sugahara M; Higa R; Wakakura M; Tomita G
Clinical Ophthalmology 2012; 6: 111-116
48963 Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma
Janulevičienė I; Derkač I; Grybauskiene L; Paulauskaitė R; Gromnickaite R; Kuzmienė L
Clinical Ophthalmology 2012; 6: 103-109
48735 Comparison of human ocular distribution of bimatoprost and latanoprost
Ichhpujani P; Katz LJ; Hollo G; Shields CL; Shields JA; Marr B; Eagle R; Alvim H; Wizov SS; Acheampong A; Chen J; Wheeler LA
Journal of Ocular Pharmacology and Therapeutics 2012; 28: 134-145
48695 In vitro study of antiadipogenic profile of latanoprost, travoprost, bimatoprost, and tafluprost in human orbital preadiopocytes
Choi HY; Lee JE; Lee JW; Park HJ; Jung JH
Journal of Ocular Pharmacology and Therapeutics 2012; 28: 146-152
49356 Sustained intraocular pressure reduction throughout the day with travoprost ophthalmic solution 0.004%
Dubiner HB; Noecker R
Clinical Ophthalmology 2012; 6: 525-531
48660 Dose response for travoprost® in the glaucomatous beagle
MacKay EO; McLaughlin M; Plummer CE; Ben-Shlomo A; Gelatt KN
Veterinary Ophthalmology 2012; 15: 31-35
48966 Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye
Natarajan JV; Ang M; Darwitan A; Chattopadhyay S; Wong TT; Venkatraman SS
International Journal of Nanomedicine 2012; 7: 123-131
49176 Spanish multicenter tafluprost tolerability study
Milla E; Stirbu O; Rey A; Duch S; Buchacra O; Robles A; Navarro C; Gil R; Cordero JM
British Journal of Ophthalmology 2012; 96: 826-831
48853 Addition of a fixed combination of brinzolamide 1%/timolol 0.5% to prostaglandin monotherapy in patients with glaucoma or ocular hypertension
Lorenz K; Rosbach K; Matt A; Pfeiffer N
Clinical Ophthalmology 2011; 5: 1745-1750
49217 Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial
Nakakura S; Tabuchi H; Baba Y; Maruiwa F; Ando N; Kanamoto T; Kiuchi Y
Clinical Ophthalmology 2012; 6: 369-375
48532 A cannabinoid ligand, anandamide, exacerbates endotoxin-induced uveitis in rabbits
Altinsoy A; Dilekö,z E; Kul O; Ilhan SÖ,; Tunccan OG; Seven I; Bagriacik EU; Sarioglu Y; Or M; Ercan ZS
Journal of Ocular Pharmacology and Therapeutics 2011; 27: 545-552
48672 Effect of prostaglandin analogues on tear proteomics and expression of cytokines and matrix metalloproteinases in the conjunctiva and cornea
Lopilly Park HY; Kim JH; Lee KM; Park CK
Experimental Eye Research 2012; 94: 13-21